MedTrace Logo

Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia

NCT07512843 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-04-06

No results posted yet for this study

Summary

The study aimed to test whether group reminiscence intervention for inpatients with schizophrenia is feasible, acceptable and preliminary effective. The effect of the intervention was evaluated on cognition, communication, and social function. Phase I was a multi-phase parallel study (n=38). The purpose of the study was to assess feasibility and preliminary efficacy by conducting an 8-week intervention with the participants. The study employed a single-group pretest-posttest evaluation. Phase II evaluated acceptability and performed a thematic analysis of semi-structured interviews conducted by a purposively selected subsample (N=8).

Conditions

  • Schizophrenia Cognition Autobiographical Memory Cognitive Remediation
  • SCHIZOPHRENIA 1 (Disorder)
  • Hospitalized Adult Patients

Interventions

BEHAVIORAL

Group reminiscence therapy

The group reminiscence intervention included 8 sessions delivered over 4 weeks, with two sessions per week. Groups consisted of 3-4 participants, with 11 groups in total. Each session lasted 80-90 minutes, with careful management to limit discussion of hallucinations and delusions. Sessions followed four stages: reconnection to build rapport and trust, reflection to stimulate autobiographical recall using active listening, restating to summarize contributions, and closure emphasizing confidentiality. Trauma-informed and psychologically supportive principles guided all sessions, including sensitive handling of difficult memories. Content covered life domains such as childhood, family, and hospital experiences, with focus on coping and meaning-making. Multisensory culturally familiar stimuli were used to enhance engagement, including traditional foods, games, and music. Confidentiality was reinforced, and participants received a small appreciation gesture at the final session.

Sponsors & Collaborators

  • The Hashemite University

    lead OTHER

Principal Investigators

  • Abdallah Abu khait, Ph.D., RN, PMHCNS, MSN, BSN · The Hashemite University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-08-29
Completion
2025-12-28

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07512843 on ClinicalTrials.gov